A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
This study is testing a new medication called CGX1321, both by itself and mixed with other approved cancer treatments, to see how well it fights advanced solid tumors and digestive system cancers. Researchers want to find the safest and most effective dose to help patients with cancers that have been hard to treat.
Adults aged 18 and older who have advanced solid tumors or gastrointestinal cancers that can be measured on scans may be able to join. Participants need to have a life expectancy of at least three months and good general health as shown by blood tests.
Depending on the study phase, participants will receive the investigational drug CGX1321 either alone or combined with other cancer medications like pembrolizumab, encorafenib, or cetuximab. Doctors will closely monitor your safety, how your body processes the medicine, and how well the treatment works against your cancer.
The study has locations in places like Long Beach and Santa Rosa in California, as well as Denver, Colorado. The current recruitment status is unknown, so it is best to contact the study locations directly for the latest updates.
- 1Tests a new cancer medication called CGX1321 alone and with other treatments.
- 2Open to adults with advanced solid tumors or digestive system cancers.
- 3Focuses on finding safe doses and watching how well the treatments work.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.